BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

BioNews
Biotechnology, Pharmaceutical and Life Science News
search help

Search Results

Documents 1-10 out of 10 found
  Current Search:  zegerid: 10     

HTML
100%
Santarus Prevails on Claims Disputed by Par Pharmaceutical at Markman Hearing
- Santarus, Inc.

(NASDAQ:SNTS), a specialty pharmaceutical company, today announced that Chief Judge Gregory M.

Sleet of the U.S.

District Court for the District of Delaware has ruled in favor of Santarus and the University of Missouri...

Pharma Live:  Nov 6 2008 4:49PM
Matching: zegerid
Find similar documents
HTML
100%
Santarus Prevails on Claims Disputed by Par Pharmaceutical at Markman Hearing
SAN DIEGO-- (BUSINESS WIRE) -- Santarus, Inc.

(NASDAQ:SNTS), a specialty pharmaceutical company, today announced that Chief Judge Gregory M.

Sleet of the U.S.

District Court for the District of Delaware has ruled in favor of Santarus...

SmartBrief:  Nov 6 2008 4:34AM
Matching: zegerid
Find similar documents
HTML
100%
Santarus Prevails on Claims Disputed by Par Pharmaceutical at Markman Hearing
Santarus, Inc.

(NASDAQ:SNTS), a specialty pharmaceutical company, today announced that Chief Judge Gregory M.

Sleet of the U.S.

District Court for the District of Delaware has ruled in favor of Santarus and the University of Missouri...

Genetic Engineering News:  Nov 6 2008 12:46AM
Matching: zegerid
Find similar documents
HTML
100%
Santarus Prevails on Claims Disputed by Par Pharmaceutical at Markman Hearing
- Santarus, Inc.

(NASDAQ:SNTS), a specialty pharmaceutical company, today announced that Chief Judge Gregory M.

Sleet of the U.S.

District Court for the District of Delaware has ruled in favor of Santarus and the University of Missouri...

DiGiTAL50:  Nov 6 2008 8:59AM
Matching: zegerid
Find similar documents
HTML
100%
Santarus Prevails on Claims Disputed by Par Pharmaceutical at Markman Hearing
SAN DIEGO--(BUSINESS WIRE)--Santarus, Inc.

(NASDAQ:SNTS - News), a specialty pharmaceutical company, today announced that Chief Judge Gregory M.

Sleet of the U.S.

District Court for the District of Delaware has ruled in favor of...

Business Wire via Yahoo!:  Nov 5 2008 11:24PM
Matching: zegerid
Find similar documents
HTML
100%
Santarus Prevails on Claims Disputed by Par Pharmaceutical at Markman Hearing
Business Editors/Health/Medical Writers SAN DIEGO--(BUSINESS WIRE)--November 5, 2008--Santarus, Inc.

(NASDAQ:SNTS), a specialty pharmaceutical company, today announced that Chief Judge Gregory M.

Sleet of the U.S.

District Court for...

Macro World Investor:  Nov 5 2008 10:24PM
Matching: zegerid
Find similar documents
HTML
100%
Santarus Prevails on Claims Disputed by Par Pharmaceutical at Markman Hearing
Business Editors/Health/Medical Writers SAN DIEGO--(BUSINESS WIRE)--November 5, 2008--Santarus, Inc.

(NASDAQ:SNTS), a specialty pharmaceutical company, today announced that Chief Judge Gregory M.

Sleet of the U.S.

District Court for...

Calibre Macro World:  Nov 5 2008 10:09PM
Matching: zegerid
Find similar documents
HTML
100%
Santarus Reports Third Quarter 2008 Financial Results
- Santarus, Inc.

(NASDAQ:SNTS), a specialty pharmaceutical company, today reported financial and operating results for the quarter ended September 30, 2008.

Key financial results for the 2008 third quarter include: He added, Business...

DiGiTAL50:  Nov 4 2008 8:49AM
Matching: zegerid
Find similar documents
HTML
100%
Santarus Reports Third Quarter 2008 Financial Results
Zegerid Quarterly Net Product Sales up 44% over Prior Year Period Updating 2008 Outlook, Guiding to Higher Revenue and Lower Net Loss SAN DIEGO--(BUSINESS WIRE)--Nov.

3, 2008--Santarus, Inc.

(NASDAQ:SNTS), a specialty...

Pharma Live:  Nov 4 2008 1:41PM
Matching: zegerid
Find similar documents
HTML
100%
Santarus Reports Third Quarter 2008 Financial Results
Santarus, Inc.

(NASDAQ:SNTS), a specialty pharmaceutical company, today reported financial and operating results for the quarter ended September 30, 2008.

Key financial results for the 2008 third quarter include: -- Total revenues of $32...

Genetic Engineering News:  Nov 3 2008 10:34PM
Matching: zegerid
Find similar documents


 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2008 - BioPortfolio Limited.